Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy.
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
The risk of fracture in incident multiple sclerosis patients: The Danish National Health Registers.
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium.
1st International Symposium on Gait and Balance in MS: Gait and Balance Measures in the Evaluation of People with MS.
[Immunodepressive therapy in neurology].
A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Role of the innate and adaptive immune responses in the course of multiple sclerosis.
Riluzole increases glutamate uptake by cultured C6 astroglial cells.
Is the treatment of multiple sclerosis headed in the wrong direction?
Alteration of CD1 expression in multiple sclerosis.
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis.
Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
The Role of CD8+ T Cells and Their Local Interaction with CD4+ T Cells in Myelin Oligodendrocyte Glycoprotein35-55-Induced Experimental Autoimmune Encephalomyelitis.
Smoking and Risk of Multiple Sclerosis: Evidence of Modification by NAT1 Variants.
Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review.
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
Pages
« first
‹ previous
…
196
197
198
199
200
201
202
203
204
…
next ›
last »